share_log

東陽光長江藥業：持續關連交易 分成協議及修訂分成協議的建議年度上限

HEC CJ PHARM: CONTINUING CONNECTED TRANSACTIONS IN RELATION TO SHARING AGREEMENT AND REVISION OF PROPOSED ANNUAL CAP UNDER THE SHARING AGREEMENT

Hong Kong Stock Exchange ·  Apr 26 22:45
Summary by Futu AI
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2022年12月26日與廣東東陽光藥業簽訂分成協議，該協議允許廣東東陽光藥業將其在中國境內銷售指定藥品所產生的收入或利潤分配給東陽光長江药业。該協議期限自2023年1月1日至2024年12月31日。根據協議，廣東東陽光藥業將分配集採業務10%的銷售收入及非集採業務70%的銷售收入給東陽光長江药业。此外，若廣東東陽光藥業的利潤總額超過上述收入分成總和，則需將所有利潤總額分配給東陽光長江药业。原先預計的年度上限為人民幣2.5百萬元，但實際收入分成超出預期，達到約人民幣23.0百萬元及約人民幣36.3百萬元。因此，公司決定將2024年度的年度上限修訂為人民幣70.0百萬元。該交易被視為關連交易，但由於交易金額低於5%，因此豁免獨立股東批准的規定。公司已採取補救措施加強內部控制，以確保及時披露任何不獲全面豁免的關連交易。
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2022年12月26日與廣東東陽光藥業簽訂分成協議，該協議允許廣東東陽光藥業將其在中國境內銷售指定藥品所產生的收入或利潤分配給東陽光長江药业。該協議期限自2023年1月1日至2024年12月31日。根據協議，廣東東陽光藥業將分配集採業務10%的銷售收入及非集採業務70%的銷售收入給東陽光長江药业。此外，若廣東東陽光藥業的利潤總額超過上述收入分成總和，則需將所有利潤總額分配給東陽光長江药业。原先預計的年度上限為人民幣2.5百萬元，但實際收入分成超出預期，達到約人民幣23.0百萬元及約人民幣36.3百萬元。因此，公司決定將2024年度的年度上限修訂為人民幣70.0百萬元。該交易被視為關連交易，但由於交易金額低於5%，因此豁免獨立股東批准的規定。公司已採取補救措施加強內部控制，以確保及時披露任何不獲全面豁免的關連交易。
Yichang East Sunlight Changjiang Pharmaceutical Co., Ltd. (“Dongguang Changjiang Pharmaceutical”) signed a division agreement with Guangdong Sunlight Pharmaceutical on December 26, 2022, which allows Guangdong Sunlight Pharmaceuticals to distribute revenues or profits generated by its sales of specified drugs in China to Dongsun Changjiang Pharmaceutical Industries. The Agreement shall run from 1 January 2023 to 31 December 2024. UNDER THE AGREEMENT, GUANGDONG SUNSHINE PHARMACEUTICALS WILL ALLOCATE 10% OF THE SALES REVENUE OF THE GATHERING BUSINESS AND 70% OF THE SALES REVENUE OF THE NON-COLLECTION BUSINESS TO DONGSUN CHANGJIANG PHARMACEUTICALS. IN ADDITION, IF THE TOTAL PROFIT OF GUANGDONG SUNSHINE PHARMACEUTICALS EXCEEDS THE AFOREMENTIONED REVENUE BREAKDOWN SUM, ALL PROFITS SHOULD BE ALLOCATED TO DONGSUN CHANGJIANG PHARMACEUTICALS. The annual cap was originally expected to be RMB2.5 million, but the actual revenue...Show More
Yichang East Sunlight Changjiang Pharmaceutical Co., Ltd. (“Dongguang Changjiang Pharmaceutical”) signed a division agreement with Guangdong Sunlight Pharmaceutical on December 26, 2022, which allows Guangdong Sunlight Pharmaceuticals to distribute revenues or profits generated by its sales of specified drugs in China to Dongsun Changjiang Pharmaceutical Industries. The Agreement shall run from 1 January 2023 to 31 December 2024. UNDER THE AGREEMENT, GUANGDONG SUNSHINE PHARMACEUTICALS WILL ALLOCATE 10% OF THE SALES REVENUE OF THE GATHERING BUSINESS AND 70% OF THE SALES REVENUE OF THE NON-COLLECTION BUSINESS TO DONGSUN CHANGJIANG PHARMACEUTICALS. IN ADDITION, IF THE TOTAL PROFIT OF GUANGDONG SUNSHINE PHARMACEUTICALS EXCEEDS THE AFOREMENTIONED REVENUE BREAKDOWN SUM, ALL PROFITS SHOULD BE ALLOCATED TO DONGSUN CHANGJIANG PHARMACEUTICALS. The annual cap was originally expected to be RMB2.5 million, but the actual revenue split exceeded expectations, reaching about RMB23.0 million and about RMB36.3 million. Therefore, the company decided to revise the annual cap for 2024 to RMB 70.0 million. The transaction is considered a connected transaction, but is exempt from the requirement of independent shareholder approval as the transaction amount is less than 5%. The Company has taken remedial measures to strengthen internal controls to ensure timely disclosure of any connected transactions that are not fully exempt.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.